Genesis 2013: Biotech urged to consider NHS partnering and venture capital
The UK’s brightest bioscience companies met in London for the One Nucleus Genesis 2013 conference on Thursday.
The day opened with a recorded video message from Mayor of London Boris Johnson telling delegates that London was the “perfect enclave” to create the largest life sciences cluster in Europe, if not the world. Harriet Fear, chief executive of hosts One Nucleus, told delegates in her welcome speech that the event was aimed to maximize the UK’s “global competitiveness.” Although she admitted “it continues to be a really tough environment,” she hailed the developments in the UK’s bioscience industry, such as the building of the Francis Crick Institute for medical research, UK pharma major AstraZeneca’s (LSE: AZN) recent commitment to the UK, and the UK Dementia Consortium announced on Wednesday.
“The NHS is changing”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze